Laboratory tests in primary care · by Dr Solange Déplanque and Dr Michaël Rochoy

Treatment: cancer immunotherapy (anti-PD-1, anti-PD-L1, anti-CTLA-4)

Oncology · Treatment monitoring · updated 2026-10-31

BioMG follows French guidelines. Adapt it to the guidelines and the tests available where you practise.

Frequency: In France, 132 924 patients started anti-PD-1 or anti-PD-L1 immunotherapy between 2014 and 2021, all indications combined (cumulative number over eight years, not annual; anti-CTLA-4 agents are not included) [1].

Before the first infusion

Fasting sample.

Fasting laboratory tests, 10 to 15 days before the first infusion

Urine tests

Detailed explanation and international comparison (in French): read it in English (machine translation)

Do not order

During treatment (before each cycle)

Fasting sample.

Before each infusion

At each cycle for 6 months, then every 2 cycles

During the first 4 cycles, then every 3 months

Detailed explanation and international comparison (in French): read it in English (machine translation)

Do not order

Fatigue, malaise or new symptom on immunotherapy

Laboratory tests the same day

Detailed explanation and international comparison (in French): read it in English (machine translation)

After stopping immunotherapy

Fasting sample.

At 1 month, 3 months and 6 months after stopping

Every month for 6 months

Between 6 and 12 months after stopping

Detailed explanation and international comparison (in French): read it in English (machine translation)

Sources (11)
  1. Grumberg V, Cotté F-E, Giroux-Leprieur E, Gaudin A-F. Clinical benefit of anti-PD-(L)1 immunotherapies in advanced cancer in France: a population-based estimate from 2014 to 2021. ESMO Open 2024;9(2):102240.
  2. Castinetti F, Albarel F, Archambeaud F, et al. French Endocrine Society Guidance on endocrine side effects of immunotherapy. Endocr Relat Cancer. 2019;26(2):G1-G18.
  3. Jary M, Coutzac C, Bonnet D, et al. Bilan pré-thérapeutique et surveillance des immunothérapies en oncologie digestive. Thésaurus national de cancérologie digestive (TNCD), chapitre 26, SNFGE, version du 24/11/2025.
  4. Assurance maladie. Nomenclature des actes de biologie médicale (NABM), version 105 : actes 1207 (T4 libre), 1208 (TSH), 1211 (TSH + T4 libre) et 1577 (HbA1c).
  5. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF). S3-Leitlinie Supportive Therapie bei onkologischen PatientInnen, Langversion 2.1, février 2026, chapitre 13 (effets immunomédiés des inhibiteurs de point de contrôle) (Allemagne).
  6. Brahmer JR, Abu-Sbeih H, Ascierto PA, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer. 2021;9(6):e002435.
  7. Husebye ES, Castinetti F, Criseno S, et al. Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline. Eur J Endocrinol. 2022;187(6):G1-G21.
  8. Velindre University NHS Trust, Medicines Management Group. South East Wales Immunotherapy Toxicity Guidelines (v3), octobre 2022 (guide régional, pays de Galles, Royaume-Uni).
  9. Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2018;36(17):1714-1768 (mise à jour 2021 non lue).
  10. Higham CE, Olsson-Brown A, Carroll P, et al. Society for Endocrinology endocrine emergency guidance: acute management of the endocrine complications of checkpoint inhibitor therapy. Endocr Connect. 2018;7(7):G1-G7.
  11. Cancer Institute NSW, eviQ. Management of immune-related adverse events (irAEs), ID 1993 v.6, revue le 23 septembre 2026 (Australie).